BioPharma Dive 28. Jan. 2026 Drugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts
BioPharma Dive 26. Jan. 2026 China’s edge in early-stage drugmaking ‘likely to persist,’ Pitchbook says
BioPharma Dive 26. Jan. 2026 Sarepta, battling slowing sales, claims Duchenne gene therapy’s impact grows with time
BioPharma Dive 26. Jan. 2026 The formula for biotech success in 2026: Confidence, resilience and funding
BioPharma Dive 26. Jan. 2026 From detection to prevention: How sponsored testing can transform patient outcomes
BioPharma Dive 26. Jan. 2026 The crucial role of raw material selection for success in cell therapy manufacturing
BioPharma Dive 23. Jan. 2026 Novo climbs higher on ‘strong’ Wegovy pill launch; Terns tweaks leukemia drug deal